Effect of glucose and insulin on oxidized low-density lipoprotein phagocytosis by human monocytes: a pilot study.
We assessed the effect of glucose and insulin on human monocytes. Monocytes were isolated from 16 healthy obese and 10 lean healthy participants. Insulin sensitivity was assessed by euglycemic hyperinsulinemic clamp. Obese participants were subdivided into 2 subgroups: insulin sensitive (IS) and insulin resistant (IR). Monocyte oxidized low-density lipoprotein (oxLDL) phagocytosis was assessed pre and poststimulation in vitro with glucose or insulin. Experiments were repeated after incubation with a Na(+)/H(+) exchanger-1 inhibitor ([NHE-1]; cariporide) or rosiglitazone. Glucose increased oxLDL phagocytosis in all groups studied (at 1 or 3 hours incubation; P = .037-.002). Insulin increased oxLDL phagocytosis in all groups studied after 1-hour incubation (P = .027-.015) but not at 3 hours. Incubation with cariporide attenuated oxLDL phagocytosis except in the obese IS group. Rosiglitazone eliminated glucose- and insulin-induced increase in oxLDL phagocytosis in all studied groups. Glucose and insulin induce oxLDL phagocytosis.
Sarigianni
Maria
M
Metabolic Diseases Unit, Second Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Bekiari
Eleni
E
Tsapas
Apostolos
A
Topouridou
Konstantina
K
Kaloyianni
Martha
M
Koliakos
George
G
Paletas
Konstantinos
K
D000293:Adolescent; D000328:Adult; D015992:Body Mass Index; D016022:Case-Control Studies; D018929:Cell Culture Techniques; D005260:Female; D005947:Glucose / Q000494:pharmacology*; D006146:Guanidines; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D009765:Obesity / Q000378:metabolism* / Q000473:pathology; D010587:Phagocytosis / Q000187:drug effects*; D010865:Pilot Projects; D000077154:Rosiglitazone; D013450:Sulfones; D013549:Sweetening Agents / Q000494:pharmacology; D045162:Thiazolidinediones; D055815:Young Adult
D006146:Guanidines; D007004:Hypoglycemic Agents; D007328:Insulin; D008077:Lipoproteins, LDL; D013450:Sulfones; D013549:Sweetening Agents; D045162:Thiazolidinediones; C099252:oxidized low density lipoprotein; D000077154:Rosiglitazone; C093373:cariporide; D005947:Glucose